Celldex's pipeline is comprised of therapeutic antibodies, antibody drug conjugates (ADCs), immune system modulators and other protein-based therapeutics that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications. This has created a leading pipeline in immunotherapy and other targeted therapies with six company-led clinical trials across six product candidates, including a registration study in triple negative breast cancer and five Phase 1 and Phase 2 clinical trials in a range of difficult-to-treat indications, and a robust preclinical engine.

Celldex-Sponsored Studies

Third-Party Sponsored Studies